Key Takeaways
- Federal Minister Syed Mustafa Kamal highlighted six critical pharmaceutical sub-sectors at the recent investment conference.
- The event aimed to promote investment, technology transfer, and local industry in Pakistan's pharmaceutical sector.
- Six key areas were identified for potential collaboration between Pakistani and Chinese entities.
Federal Minister for National Health Services, Regulations and Coordination, Syed Mustafa Kamal, addressed the recent 'Pakistan-China B2B Investment Conference 2026', emphasizing the importance of six key pharmaceutical sub-sectors. These sectors were chosen to foster investment and technological advancements in Pakistan's healthcare industry.
During his statement, Minister Kamal stated that special attention was given to these areas during the conference, which took place on Wednesday. The minister highlighted the potential for significant growth and development within these sectors through increased collaboration with Chinese partners.
The six key pharmaceutical sub-sectors identified include biotechnology, medical devices, generics, vaccines, diagnostics, and traditional medicines. Each of these areas was discussed in detail during the conference to explore opportunities for joint ventures and partnerships between Pakistani and Chinese companies.
According to Minister Kamal, the primary objective of the conference was to attract foreign investment into Pakistan's pharmaceutical sector while also facilitating technology transfer and enhancing local industry capabilities. He emphasized that this would not only boost economic growth but also improve healthcare services in the country.
The minister further stated that the government is committed to creating a conducive environment for investors, ensuring regulatory support and providing incentives to encourage participation from both domestic and international players. These measures are expected to drive innovation and competitiveness within Pakistan's pharmaceutical landscape.
Attendees at the conference included representatives from various Pakistani pharmaceutical companies as well as Chinese firms interested in expanding their presence in the region. The discussions focused on identifying specific projects and initiatives that could be pursued jointly, with an aim to accelerate the development of these critical sub-sectors.
Minister Kamal concluded by expressing optimism about the future prospects for collaboration between Pakistan and China in the pharmaceutical sector. He stated, 'We are confident that this partnership will lead to significant advancements in our healthcare industry and contribute positively to the overall economic growth of both countries.'
'We are confident that this partnership will lead to significant advancements in our healthcare industry and contribute positively to the overall economic growth of both countries.'
Syed Mustafa Kamal, Federal Minister for National Health Services, Regulations and Coordination, Federal Minister
